• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Advances in CAR T-Cell Therapy and Bispecifics for Relapse/Refractory Multiple Myeloma: Insights From ESMO Congress 2024

by | Sep 17, 2024 | Myeloma News

Source: Pharmacy Times articles The efficacy and safety profiles of CAR T-cell and bispecific antibody therapies have led to their investigation in earlier lines of therapy, with several new treatments in development. Read More

Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets

by | Sep 14, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Correction: Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1

by | Sep 13, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Bispecific antibodies in the treatment of multiple myeloma

by | Sep 12, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Next-gen oncology: the role of CAR-T cells against ocular lymphoma and myeloma

by | Sep 12, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma

by | Sep 11, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Advancements in Multiple Myeloma Therapies and Operational Insights in Oncology Clinical Trials
  • Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
  • Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
  • ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
  • Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
  • Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
  • Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT